J&J (NYSE:JNJ) announced on Tuesday that its FDA-approved antibody therapy, Tremfya, as a subcutaneous option, improved a range of clinical and endoscopic measures in patients with the intestinal disorder ulcerative colitis who participated in a Phase 3 trial.
Citing data from its Phase 3 ASTRO study, the New Jersey-based pharma giant said Tremfya injectable as an induction and maintenance therapy caused clinically meaningful improvements across all clinical and endoscopic measures against placebo.
J&J (NYSE:JNJ) previously posted 12-week SC induction data from ASTRO, noting that Tremfya, approved in the U.S. as SC and IV induction options for ulcerative colitis as well as Crohn’s disease, improved all clinical and endoscopic measures with statistically significant and clinically meaningful effects.
The ASTRO results were among a series of abstracts selected for presentation at the United European Gastroenterology Week 2025, taking place in Berlin this week.
“This latest development offers patients and providers the choice of starting treatment for UC with a self-administered subcutaneous injection, with the same efficacy and safety that were established with IV induction,” said Esi Lamousé-Smith, J&J’s (NYSE:JNJ) Gastroenterology Disease Area Lead.